Princeton-based WIRB-Copernicus Group WCG Clinical Services Division announced the acquisition of Analgesic Solutions LLC, a developer of pain medications and supporter of clinical trials in which pain is an indicator of an underlying condition. Analgesic Solutions joins the family of WCG clinical services that facilitate and optimize the conduct of clinical trials. WCG’s newest addition focuses on increasing assay sensitivity in clinical trials through consulting, innovative tools, data science, technology and specialized training. “We are delighted to welcome Dr. Nathaniel Katz, the founder and chief scientist of Analgesic Solutions, and his extraordinary team of clinicians and scientists to WCG,” said Donald Deieso, executive chairman and chief executive officer of WCG, in a statement. “The intense public focus on developing alternatives to opioids for use in pain management, as well the organization’s deep understanding of patients’ subjective … [Read more...] about WCG acquires Analgesic Solutions
DALLAS, TEXAS, USA, February 27, 2019 /EINPresswire.com/ -- CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas, announced today that their Investigational New Drug (IND) application for CT-044 has received notification from the United States Food and Drug Administration (FDA) indicating that its Phase I safety and tolerability clinical trial may proceed. CT-044, a non-metal based, orally bioavailable, small molecule Radical Species Decomposition Accelerant (RSDAx) of peroxynitrite and hydrogen peroxide, is proposed for the treatment of acute and chronic pain, including acute post-surgical pain and painful diabetic neuropathy. “Notification that our first study in the clinic may proceed marks a tremendous milestone for CerSci Therapeutics,” said Co-Founder and Chief Executive Officer Dr. Lucas Rodriguez. The transition of CT-044 from pre-clinical development into the clinic offers hope for patients needing an alternative to opiates in the … [Read more...] about CerSci Therapeutics Announces FDA Notification that First Clinical Trial of Non-Opioid Analgesic for Pain May Proceed
LONDON, GREATER LONDON, UK, October 24, 2018 /EINPresswire.com/ -- Drugs to treat osteoarthritis, together with analgesics and immunosupressives, were worth $82 billion to the global pharmaceutical industry in 2017, a new report from The Business Research Company, Pharmaceutical Drugs Global Market Opportunities And Strategies To 2021, shows. This part of the pharmaceutical market will increase in size to $117 billion by 2021, when it will account for 75% of the world’s largest pharma market, that for musculoskeletal drugs. The other segments, drugs for rheumatoid arthritis and muscle relaxants, will then be worth $60 billion between them to the drug industry. Many musculoskeletal disorders are incurable so that patients will take these pain- and inflammation-reducing drugs either continuously or periodically for life. As their incidence is age-related, the increase in the size of the aging population is one factor driving the growth of this segment of the pharma industry. Other … [Read more...] about Osteoarthritis, Analgesic And Immunosupressive Drugs Increasingly Dominate The Musculoskeletal Drugs Market
Central Nervous System Drugs Global Market Size 2021 LONDON, GREATER LONDON, UK, June 21, 2018 /EINPresswire.com/ -- The global market for analgesics, which includes opioids as well as anti-inflammatory drugs to relieve localized pain, is growing at over 8% year on year, a report from The Business Research Company shows. This compares with 6% for anaesthetics and 5% for anti-Parkinson drugs. Analgesics are drugs that relieve pain selectively without blocking the conduction of nerve impulses, noticeably changing sensory perception, or affecting consciousness. There are two types of analgesics – anti-inflammatory drugs that relieve modest pain by reducing local inflammatory responses and the opioids that act on the brain to reduce chronic pain. In some parts of the world, such as the USA, experts suggest, there is an opioid crisis, resulting from the addictive properties of these drugs. It is claimed that more than two million Americans have become dependent on or abused … [Read more...] about Opioids and Other Analgesics Are The Fastest-Growing Neurology Drugs
Glen Rock, N.J., June 19, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on June 13, 2018, it entered into a letter of intent (“LOI”) with Noramco, Inc., pursuant to which the parties have entered into a ninety-day period during which they will negotiate a definitive agreement regarding the Company’s development of dronabinol. Subject to successful completion of due diligence and execution of a definitive agreement, the Company and Noramco will cooperate in the co-development of both a first-generation gel capsule of dronabinol in sesame oil and a second-generation modified formulation of dronabinol with enhanced pharmaceutical properties. Dronabinol is a synthetic cannabinoid, also known as Δ9-tetrahydrocannabinol or Δ9-THC and is approved and marketed by other companies both as a branded product and in generic formulations for anorexia … [Read more...] about Advancing Dronabinol Obstructive Sleep Apnea Program with Letter of Intent for Co-Development and Supply Agreement with Noramco, Inc.